GALAPAGOS NV/S (NASDAQ:GLPG) has received an average recommendation of “Hold” from the twenty ratings firms that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and eight have issued a buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $229.00.
GLPG has been the subject of several research analyst reports. HC Wainwright lowered their price objective on shares of GALAPAGOS NV/S from $302.00 to $270.00 and set a “buy” rating for the company in a research report on Thursday, May 21st. Bank of America downgraded shares of GALAPAGOS NV/S from a “neutral” rating to an “underperform” rating and set a $213.00 price objective for the company. in a research report on Monday, February 24th. TheStreet downgraded shares of GALAPAGOS NV/S from a “b” rating to a “c” rating in a report on Wednesday, May 6th. Royal Bank of Canada reiterated a “hold” rating and set a $155.00 price target on shares of GALAPAGOS NV/S in a report on Monday, April 13th. Finally, Citigroup downgraded shares of GALAPAGOS NV/S from a “neutral” rating to an “underperform” rating and set a $213.00 price target for the company. in a report on Monday, February 24th. They noted that the move was a valuation call.
GLPG traded up $1.73 during trading on Monday, hitting $195.41. 89,524 shares of the stock traded hands, compared to its average volume of 130,230. GALAPAGOS NV/S has a twelve month low of $112.00 and a twelve month high of $274.03. The company has a market cap of $12.55 billion, a price-to-earnings ratio of 37.17 and a beta of 1.23. The company has a debt-to-equity ratio of 0.01, a current ratio of 9.28 and a quick ratio of 9.28. The business has a 50 day moving average price of $210.17 and a 200 day moving average price of $211.34.
Institutional investors and hedge funds have recently modified their holdings of the business. Harbor Investment Advisory LLC purchased a new stake in shares of GALAPAGOS NV/S during the 1st quarter valued at $31,000. Oppenheimer Asset Management Inc. purchased a new position in GALAPAGOS NV/S in the 1st quarter worth $36,000. RMR Wealth Builders purchased a new position in GALAPAGOS NV/S in the 4th quarter worth $82,000. Sowell Financial Services LLC raised its position in GALAPAGOS NV/S by 437.0% in the 1st quarter. Sowell Financial Services LLC now owns 537 shares of the biotechnology company’s stock worth $105,000 after purchasing an additional 437 shares during the period. Finally, SG Americas Securities LLC purchased a new position in GALAPAGOS NV/S in the 4th quarter worth $113,000. 11.71% of the stock is currently owned by institutional investors and hedge funds.
About GALAPAGOS NV/S
Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.
See Also: What is a Roth IRA?
Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.